Abstract: Neuro-psychiatric disorders represent one of the most complex and pressing challenges in modern medicine. These conditions, ranging from schizophrenia and Parkinson’s disease to Alzheimer’s and mood disorders, are characterized by multifactorial etiologies, overlapping symptomatology, and often unpredictable therapeutic responses. Despite decades of research, the pharmacological management of these disorders remains suboptimal, with many patients experiencing limited efficacy, delayed onset of action, or debilitating side effects. A growing body of evidence points to shared pathological mechanisms across neurodegenerative and psychiatric conditions, including intracerebral protein aggregation, mitochondrial dysfunction, abnormal iron accumulation, oxidative stress, and ferroptosis-induced neuronal death. These converging pathways underscore the need for therapeutic strategies that go beyond symptomatic relief to address underlying molecular dysfunctions. In this context, this thematic issue brings together a collection of cutting-edge research articles that reflect the latest advances in drug design, development, and delivery strategies to improve therapeutic outcomes in neuropsychiatric care. This issue is a curated effort to bridge the gap between molecular innovation and clinical translation. It highlights how interdisciplinary approaches spanning medicinal chemistry, pharmacogenomics, molecular docking, and natural product research are converging to redefine the therapeutic landscape. From enzyme-targeted therapies and marine-derived neuroprotectants to prolactin-sparing antipsychotics and precision medicine frameworks, each manuscript contributes a unique perspective to this evolving field. Collectively, these studies illuminate promising avenues for personalized, mechanism-based interventions that may transform the future of neuropsychiatric treatment. This issue aspires to serve not only as a scholarly resource but also as a catalyst for innovation and collaboration across disciplines.
Tiwari et al. (Wed,) studied this question.